Opticyte is a startup company and a spin out of the University of Washington. The company was formed to commercialize a next-generation oximeter that will allow clinicians real-time monitoring of cellular oxygenation and perfusion.
The CellSat™ oximetry technology has been refined in the Schenkman Laboratory at the University of Washington. With $3.0M in non-dilutive funding from the NIH, Coulter Foundation, WA Life Sciences Discovery Fund, NIH STTR Phase I, SBIR Phase II, CoMotion Innovation, and Medic One, the technology has made significant strides toward de-risking the measurement of myoglobin oxygenation in skeletal muscle and the use of that measurement in the emergency department.
Opticyte incorporated in May 2016 prior to signing an exclusive license agreement with the University of Washington. Cofounders include Robert V. Masterson, CEO, and serial entrepreneur including past CEO of Prevencio and Onconome (Tessera Diagnostics); Kenneth A. Schenkman, MD, PhD, and critical care physician at Seattle Children’s Hospital, Lorilee Arakaki, PhD, UW research scientist in optical spectroscopy, and Wayne Ciesielski, UW research scientist.